29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)

27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)

22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)

13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis

21/11/2022 – AB Science today announced that it has received an Investigational New Drug (IND) approval letter from the FDA to initiate Phase III study (AB21004) in patients with mild to moderate Alzheimer’s disease

10/10/2022 – AB Science today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease